- Home
- RSLS vs EVOK Comparison
RSLS vs EVOK Comparison
Compare RSLS & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- EVOK
- Stock Information
- Founded
- RSLS 2002
- EVOK 2007
- Country
- RSLS United States
- EVOK United States
- Employees
- RSLS N/A
- EVOK N/A
- Industry
- RSLS Medical/Dental Instruments
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- EVOK Health Care
- Exchange
- RSLS Nasdaq
- EVOK Nasdaq
- Market Cap
- RSLS 4.5M
- EVOK 4.2M
- IPO Year
- RSLS 2007
- EVOK 2013
- Fundamental
- Price
- RSLS $2.56
- EVOK $2.50
- Analyst Decision
- RSLS Hold
- EVOK
- Analyst Count
- RSLS 1
- EVOK 0
- Target Price
- RSLS N/A
- EVOK N/A
- AVG Volume (30 Days)
- RSLS 7.3M
- EVOK 18.3K
- Earning Date
- RSLS 08-13-2025
- EVOK 08-12-2025
- Dividend Yield
- RSLS N/A
- EVOK N/A
- EPS Growth
- RSLS N/A
- EVOK N/A
- EPS
- RSLS N/A
- EVOK N/A
- Revenue
- RSLS $7,175,000.00
- EVOK $11,594,083.00
- Revenue This Year
- RSLS $52.80
- EVOK $57.82
- Revenue Next Year
- RSLS N/A
- EVOK $59.12
- P/E Ratio
- RSLS N/A
- EVOK N/A
- Revenue Growth
- RSLS N/A
- EVOK 89.89
- 52 Week Low
- RSLS $2.23
- EVOK $1.94
- 52 Week High
- RSLS $414.99
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- RSLS 36.91
- EVOK 31.35
- Support Level
- RSLS $2.45
- EVOK $2.47
- Resistance Level
- RSLS $2.87
- EVOK $3.01
- Average True Range (ATR)
- RSLS 0.68
- EVOK 0.28
- MACD
- RSLS 0.14
- EVOK -0.09
- Stochastic Oscillator
- RSLS 5.45
- EVOK 3.35
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.